TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8144850
Drug: Goserelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin depot formulation 3.6 mg every 28 days for 6 months (first implant in late luteal phase)
Study: 8144850
Drug: Goserelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin depot formulation 3.6 mg every 28 days for 6 months (first implant on 3rd and 17th day from onset of menses)
Study: 29976078
Drug: 0.1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g/kg multi-strain probiotic (MS)
Study: 29976078
Drug: 0.1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g/kg single-strain probiotic (SS)
Study: 29976078
Drug: 0.1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g/kg of both probiotics (MS+ SS)
Study: 29976078
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg oxytetracycline antibiotic (OX)
Study: 20980654
Drug: Aleurone-rich cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleurone-rich cereal products (27 g/d aleurone)
Study: 15304189
Drug: 5% ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% ascorbic acid cream
Study: 8507449
Drug: Potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate (100 mg/day, orally for 1 month)
Study: 3431029
Drug: Polyenylphosphatidylcholine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyenylphosphatidylcholine (10 g per day)
Study: 3431029
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (7 g per day)
Study: 28570305
Drug: Immersive Virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive Virtual Reality (IVR) distraction therapy
Study: 11710653
Drug: Ginseng (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (400 mg per day of G115)
Study: 9024299
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium phosphate supplementation
Study: 7984562
Drug: Specially designed
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specially designed diagnostic preparations made of TB and BCG vaccine strain tuberculin
Study: 2880497
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no beta-blocking drugs)
Study: 29247383
Drug: Platinum-based doublet
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based doublet chemotherapy
Study: 27938361
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of spa therapy, exercise, and self-management workshops for 6 days
Study: 25535778
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including sealing and no treatment)
Study: 17622255
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Zn/day
Study: 17622255
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Zn/day
Study: 17200730
Drug: Various drugs
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drugs including 5‐Methyltetrahydrofolate, (R)‐flurbiprofen, Ad5CMV‐p53, adalimumab, alefacept, alemtuzumab, Alequel, alicaforsen sodium, almotriptan, anakinra, aprepitant, aripiprazole, armodafinil, Bevacizumab, bortezomib, bosentan, Canfosfamide hydrochloride, ciclesonide, clofarabine, Cypher, Darbepoetin alfa, diclofenac potassium, drotrecogin alfa (activated), duloxetine hydrochloride, Eel calcitonin, eletriptan, eplerenone, everolimus, ezetimibe, Frovatriptan, Gefitinib, γ‐hydroxybutyrate sodium, HKI‐272, HYB‐165, Ibutamoren mesylate, imatinib mesylate, interleukin‐21, ixabepilone, KRN‐951, L‐Arginine hydrochloride, levodopal carbidopa/entacapone, Micafungin sodium, motexafin gadolinium, mycophenolic acid sodium salt, Nesiritide, Peginterferon alfa‐2a, pitavastatin calcium, pralatrexate, pregabalin, pVAX/L523S‐Ad.L523S, Rasagiline mesylate, recombinant human nerve growth factor, regadenoson, rF‐PSA, rimonabant, rizatriptan, rofecoxib, rosuvastatin calcium, rV‐B7.1, rV‐PSA, Sipuleucel‐T, sirolimus‐eluting stent, solifenacin succinate, sorafenib, sunitinib malate, Talactoferrin alfa, Taxus, tegaserod maleate, teriparatide, tipifarnib, Valdecoxib, vandetanib, vatalanib succinate, WT1‐peptide vaccine, Xaliproden hydrochloride
Study: 13129416
Drug: Oral tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral tegafur plus uracil (UFT) plus folinic acid
Study: 13129416
Drug: Intravenous fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fluorouracil (FU) plus oral folinic acid (leucovorin)
Study: 10632648
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. (RBCCT group)
Study: 10632648
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. (RBCCA group)
Study: 8619505
Drug: Inhaled exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled exposure to carbon monoxide at sea level
Study: 8619505
Drug: Inhaled exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled exposure to carbon monoxide at high altitude
Study: 8619505
Drug: Inhaled exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled exposure to clean air at sea level
Study: 8619505
Drug: Inhaled exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled exposure to clean air at high altitude
Study: 28855223
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet (low in fat and high in protein, low-fat dairy, and fruits and vegetables) with high sodium (150 nmol or 3450 mg)
Study: 28855223
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet with medium sodium (100 nmol or 2300 mg)
Study: 28855223
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet with low sodium (50 nmol or 1150 mg)
Study: 25935787
Drug: 0.3‐mg intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3‐mg intravitreal ranibizumab injection therapy
Study: 24284115
Drug: 5% ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% ALA gel applied topically for 1h incubation followed by LED light irradiation at 633 nm, 96-120 J/cm² for 3-4 sessions
Study: 19074355
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (4 weekly sessions)
Study: 19074355
Drug: Quiet-time control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quiet-time control (4 weekly sessions)
Study: 14743852
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of intravenous inotropes
Study: 11319593
Drug: Heparin (Hep)
Normalized name: heparin sodium, porcine Injectable Solution [Hep-Pak]
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin (Hep)
Study: 11319593
Drug: Heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin + Prostaglandin E1 (Hep + PGE1)
Study: 9345174
Drug: Control (alphabetical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (alphabetical list of drugs)
Study: 9345174
Drug: Limited support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited support (list of preferred drugs)
Study: 8084119
Drug: Erinit and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erinit and allopurinol in conventional therapeutical doses
Study: 27306372
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg roflumilast
Study: 27306372
Drug: 0.375 mg
Normalized name: vitamin A 0.375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375 mg roflumilast
Study: 27306372
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg roflumilast
Study: 27306372
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 0.375 mg roflumilast
Study: 26474518
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus erlotinib (150 mg once daily)
Study: 24942210
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg every 3 weeks)
Study: 21609207
Drug: Vildagliptin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 400 mg
Study: 19332727
Drug: Adjuvant doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant doxorubicin (75 mg/m(2)) followed by CMF
Study: 19332727
Drug: Adjuvant paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant paclitaxel (200 mg/m(2)) plus doxorubicin (60 mg/m(2)), followed by CMF
Study: 19332727
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m(2)) plus doxorubicin (60 mg/m(2)) followed by CMF followed by surgery
Study: 15288707
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg orally at 2300 h)
Study: 9801900
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (batch 1)
Study: 9801900
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (batch 2)
Study: 336078
Drug: Bellergal (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bellergal (combination of belladonna alkaloids, ergotamine tartrate, and phenobarbitone), administered three times daily
Study: 24655978
Drug: EVL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVL plus atorvastatin 20 mg
Study: 22979932
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for dry eye (3 weeks duration)
Study: 22979932
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear therapy (control group, 3 weeks duration)
Study: 22979932
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (1 week after treatment)
Study: 19203163
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual for juvenile sexual offenders (TAU-JSO)
Study: 17301733
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (300 ml) with 120 mg fexofenadine
Study: 17301733
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of naringin (1,200 microM) with 120 mg fexofenadine
Study: 17301733
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice with 120 mg fexofenadine
Study: 17301733
Drug: Particulate fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particulate fraction of juice with 120 mg fexofenadine
Study: 7924123
Drug: Amoxicillin administered
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin administered as a bolus (375 mg in 120 ml water)
Study: 7924123
Drug: Amoxicillin administered
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin administered as a 4-hour infusion (375 mg in 120 ml water)
Study: 7924123
Drug: Amoxicillin administered
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin administered as a bolus in the ileum
Study: 7924123
Drug: Amoxicillin administered
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin administered as a 4-hour infusion in the ileum
Study: 7924123
Drug: Amoxicillin infused
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin infused in colonic regions
Study: 7924123
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of amoxicillin solution
Study: 31942838
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg grape seed polyphenol extract (GSPE)
Study: 22882753
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sumatriptan tablet with 50 mL of water
Study: 22882753
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of water alone (control)
Study: 20335070
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg for the first day, then 75 mg daily) plus aspirin (75-160 mg daily)
Study: 20335070
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (75-160 mg daily)
Study: 19290473
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg i.v. at the end of the operation, followed by 8 mg 12 h after the operation
Study: 19290473
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg/kg at the end of the operation and every 6 h up to 24 h postoperatively
Study: 12610744
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 2.5 microg/ml
Study: 12610744
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 10 microg/ml
Study: 12610744
Drug: Reference compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference compound antipyrine (100 microg/ml)
Study: 10582898
Drug: Oral trovafloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trovafloxacin (200 mg)
Study: 10582898
Drug: Intravenous alatrofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alatrofloxacin
Study: 8692619
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg per day for 12 days, tapered progressively)
Study: 1879386
Drug: Seventeen meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seventeen meals daily
Study: 1879386
Drug: Three meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three meals daily
Study: 6603716
Drug: Netilmicin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (5 mg/kg body weight, intramuscular injection)
Study: 6603716
Drug: Netilmicin combined
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin combined with beta-Lactam antibiotics
Study: 30905227
Drug: Long-term antenatal
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antenatal indomethacin treatment (LIT)
Study: 29767754
Drug: OS‐IUI cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: OS‐IUI cycles (all treatments)
Study: 17316487
Drug: E‐Zagreb, L‐Zagreb,
Approvals — FDA: no, EMA: no, PMDA: no
Description: E‐Zagreb, L‐Zagreb, and Wistar RA 27/3 (Tresivac)
Study: 12611835
Drug: Lorazepam 6
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam 6 mg/day
Study: 9343646
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intra-articular morphine
Study: 23281420
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intra-articular morphine
Study: 9343646
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous morphine
Study: 17468821
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bupivacaine
Study: 8338088
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (Fleet Phospho‐Soda)
Study: 8338088
Drug: Standard polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard polyethylene glycol‐based lavage solution (GoLYTELY)
Study: 3505526
Drug: Verapamil 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 5 mg/2 ml
Study: 3505526
Drug: Verapamil 10
Normalized name: verapamil 100 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 10 mg/4 ml
Study: 1838690
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) infusion (0.04 micrograms/kg/min)
Study: 8038755
Drug: Vehicle (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (50 mL of isotonic saline)
Study: 6217950
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g mezlocillin
Study: 6217950
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g ampicillin plus 1.0 g probenecid orally
Study: 28784657
Drug: Cholecalciferol (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (2000 IU daily)
Study: 28784657
Drug: Calcitriol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5 μg daily)
Study: 26393990
Drug: Musical auditory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musical auditory stimulation in the control group (12 women not taking oral contraceptives)
Study: 26393990
Drug: Musical auditory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musical auditory stimulation in the oral contraceptive group (10 women taking oral contraceptives)
Study: 24038913
Drug: 3-6 years
Normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-6 years treated with irradiation and chemotherapy
Study: 24215215
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of azithromycin (AZM)
Study: 12404692
Drug: 0.66 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.66 g/kg alcohol
Study: 12404692
Drug: caffeine (110-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: caffeine (110-120 mg)
Study: 8669216
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA (2 mg/ml or 3 mg/ml)
Study: 2178869
Drug: Acetyl-l-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-l-carnitine (1 g twice daily)
Study: 2178869
Drug: Acetyl-l-carnitine
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-l-carnitine
Study: 30839477
Drug: Healthy Hip
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Hip Diaper (prophylactic treatment)
Study: 28802619
Drug: Sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2.0 mg/kg at T2 after rocuronium
Study: 28802619
Drug: Sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2.0 mg/kg at T2 after vecuronium
Study: 28802619
Drug: Sugammadex 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4.0 mg/kg at 1–2 PTC after rocuronium
Study: 28802619
Drug: Sugammadex 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4.0 mg/kg at 1–2 PTC after vecuronium
Study: 28802619
Drug: Sugammadex 16.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 16.0 mg/kg at 3 min after rocuronium 1.2 mg/kg
Study: 23018466
Drug: Subcutaneous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous bortezomib 1.3 mg/m²
Study: 23018466
Drug: Intravenous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bortezomib 1.3 mg/m²
Study: 23018466
Drug: Subcutaneous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous bortezomib 1.3 mg/m² (CAN-1004)
Study: 23018466
Drug: Intravenous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bortezomib 1.3 mg/m² (CAN-1004)
Study: 3285278
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg/day on days 1 and 2 of each week for 18 months)
Study: 31207648
Drug: Daily echocardiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily echocardiography
Study: 28669360
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) therapy via telehealth
Study: 28669360
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) therapy in person
Study: 22481619
Drug: Intra-vaginal fenticonazole
Normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-vaginal fenticonazole 600 mg
Study: 20160158
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg once daily for 4 days
Study: 12653794
Drug: Ciclesonide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (800 micro g twice daily)
Study: 1816122
Drug: Single 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 g dose of cefotaxime
Study: 1816122
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of cefotaxime
Study: 1816122
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metronidazole i.v. every 12 h for 72 h
Study: 29236165
Drug: Dose 1
Normalized name: Aldose 1-epimerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 Curry (D1C)
Study: 29236165
Drug: Dose 2
Normalized name: Fluzone High-Dose 2011-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2 Curry (D2C)